================================================================================
PURCHASE AGREEMENT
================================================================================
dated as of September __, 2003
by and between
BIOGENTECH CORP.
and
================================================================================
GRYPHON MASTER FUND, L.P.
================================================================================
================================================================================
7.5% CONVERTIBLE PREFERRED STOCK
================================================================================
and
================================================================================
================================================================================
COMMON STOCK PURCHASE WARRANT
BIOGENTECH CORP.
PURCHASE AGREEMENT
7.5% CONVERTIBLE PREFERRED STOCK
and
COMMON STOCK PURCHASE WARRANT
TABLE OF CONTENTS
Page
1. Definitions...........................................................1
2. Purchases and Sales of the Shares and Warrant.........................5
2.1 Purchase and Sale............................................5
2.2 Payment......................................................6
2.3 Closing......................................................7
3. Representations and Warranties of the Company.........................6
3.1 Organization, Good Standing and Qualification................6
3.2 Authorization................................................7
3.3 Capitalization...............................................7
3.4 Valid Issuance...............................................7
3.5 Consents.....................................................8
3.6 Delivery of SEC Filings; Business; Non-Public Information....8
3.7 Use of Proceeds..............................................8
3.8 No Material Adverse Change...................................8
3.9 Registration Statements......................................9
3.10 Form S-3 Eligibility.........................................9
3.11 No Conflict, Breach, Violation or Default...................10
3.12 Tax Matters.................................................10
3.13 Title to Properties.........................................10
3.14 Certificates, Licenses, Authorizations and Permits..........11
3.15 No Labor Disputes...........................................11
3.16 Intellectual Property.......................................11
3.17 Environmental Matters.......................................12
3.18 Litigation..................................................12
3.19 Financial Statements........................................12
3.20 Insurance Coverage..........................................12
3.21 ▇▇▇▇▇▇▇▇-▇▇▇▇▇..............................................14
3.22 Acknowledgement of Potential Dilution.......................13
3.23 Brokers and Finders.........................................13
3.24 No Directed Selling Efforts or General Solicitation.........13
3.25 No Integrated Offering......................................13
3.26 Disclosures.................................................13
3.27 Absence of Rights Agreement.................................13
-i-
4. Representations and Warranties of the Purchaser......................14
4.1 Organization and Existence..................................14
4.2 Purchase Entirely for Own Account...........................14
4.3 Investment Experience.......................................14
4.4 Disclosure of Information...................................14
4.5 Restricted Securities.......................................14
4.6 Accredited Investor.........................................14
4.7 No General Solicitation.....................................14
4.8 Residency of Purchaser......................................14
4.9 Brokers and Finders.........................................14
4.10 Authorization...............................................15
4.11 Risk Factors................................................15
4.12 Reliance....................................................15
4.13 No Representations..........................................15
4.14 Survival....................................................15
5. Registration Rights Agreement........................................15
5.1 Registration Rights Agreement...............................15
6. Certain Covenants of the Company and the Purchaser...................15
6.1 19.99% Cap; Rule 144........................................15
6.2 Limitation on Certain Transactions..........................16
6.3 Right of the Purchaser to Participate in Future
Transactions................................................16
6.4 Reports and Information.....................................18
6.5 Press Releases..............................................19
6.6 No Conflicting Agreements...................................19
6.7 Insurance...................................................19
6.8 Compliance with Laws........................................20
6.9 Listing of Underlying Shares and Warrant
Shares and Related Matters.................................20
6.10 Corporate Existence.........................................20
6.11 Form 8-K....................................................21
6.12 Legends.....................................................21
7. Conditions to the Company's Obligations to Issue and Sell............22
8. Conditions to the Purchaser's Obligations to Purchase................22
9. Miscellaneous........................................................23
9.1 Successors and Assigns......................................23
9.2 Counterparts................................................23
9.3 Titles and Subtitles........................................24
9.4 Notices.....................................................24
9.5 Expenses....................................................24
9.6 Amendments and Waivers......................................24
9.7 Severability................................................25
-ii-
9.8 Entire Agreement............................................25
9.9 Survival....................................................25
9.10 Further Assurances..........................................25
9.11 Applicable Law..............................................25
9.12 Remedies....................................................25
9.13 Jurisdiction................................................25
EXHIBITS
Exhibit A - Form of Certificate of Designation of Rights and Preferences of 7.5%
Convertible Preferred Stock
Exhibit B - Form of Warrant
Exhibit C - Form of Registration Rights Agreement
-iii-
PURCHASE AGREEMENT
------------------
THIS PURCHASE AGREEMENT dated as of September __, 2003 (this
"Agreement"), by and between BIOGENTECH CORP., a Nevada corporation (the
"Company"), and GRYPHON MASTER FUND, L.P., a Bermuda limited partnership (the
"Purchaser").
W I T N E S S E T H:
- - - - - - - - - -
WHEREAS, the Purchaser wishes to purchase from the Company,
and the Company wishes to sell and issue to the Purchaser, upon the terms and
subject to the conditions of this Agreement, (i) 1,000 shares of the Company's
7.5% Convertible Preferred Stock, par value $___ per share (the "Shares"), and
(ii) a Warrant initially entitling the holder to purchase an aggregate of
104,167 shares of Common Stock for the Purchase Price; and
WHEREAS, at or before the Closing, the parties hereto are
executing and delivering, one to the other, the Registration Rights Agreement,
pursuant to which, among other things, the Company will agree to provide certain
registration rights under the 1933 Act, and the rules and regulations
promulgated thereunder, and applicable state securities laws for the resale of
the shares of Common Stock issuable upon conversion of the Shares and issuable
upon exercise of the Warrant.
NOW THEREFORE, in consideration of the premises and the mutual
covenants made herein and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereto agree as
follows:
1. Definitions.
1.1 As used in this Agreement, the terms "Agreement",
"Company" and "Purchaser" shall have the respective meanings assigned to such
terms in the introductory paragraph of this Agreement.
1.2 All the agreements or instruments herein defined shall
mean such agreements or instruments as the same may from time to time be
supplemented or amended or the terms thereof waived or modified to the extent
permitted by, and in accordance with, the terms thereof and of this Agreement.
1.3 The following terms shall have the following meanings
(such meanings to be equally applicable to both the singular and plural forms of
the terms defined):
1
"Affiliate" means, with respect to any Person, any other
Person that directly, or indirectly through one or more intermediaries,
controls, is controlled by or is under common control with the subject Person.
For purposes of this definition, "control" (including, with correlative meaning,
the terms "controlled by" and "under common control with"), as used with respect
to any Person, shall mean the possession, directly or indirectly, of the power
to direct or cause the direction of the management and policies of such Person,
whether through the ownership of voting securities or by contract or otherwise.
"Aggregation Parties" shall have the meaning provided in
Section 6.3(b).
"AMEX" means the American Stock Exchange, Inc.
"Approved Markets" shall have the meaning provided in Section
6.9.
"Board of Directors" means the Board of Directors of the
Company.
"Business Day" means any day other than a Saturday, Sunday or
a day on which commercial banks in the City of Dallas are authorized or required
by law or executive order to remain closed.
"Certificate of Designation" means the Certificate of
Designation of Rights and Preferences of 7.5% Convertible Preferred Stock in the
form attached as EXHIBIT A.
"Change in Control Transaction" shall will be deemed to exist
if (i) there occurs any consolidation, merger, amalgamation or other business
combination of the Company with or into any other corporation or other entity or
person (whether or not the Company is the surviving corporation), or any other
corporate reorganization or transaction or series of related transactions in
which in any of such events the persons who are holders of the voting stock of
the Company immediately prior to such event cease to own 50% or more of the
voting stock, or corresponding voting equity interests, of the surviving
corporation or other entity immediately after such event (including without
limitation any "going private" transaction under Rule 13e-3 promulgated pursuant
to the 1934 Act or tender offer by the Company under Rule 13e-4 promulgated
pursuant to the 1934 Act for 20% or more of the Common Stock), (ii) any person
(as defined in Section 13(d) of the 1934 Act), together with its affiliates and
associates (as such terms are defined in Rule 405 under the 1933 Act),
beneficially owns or is deemed to beneficially own (as described in Rule 13d-3
under the 1934 Act without regard to the 60-day exercise period) in excess of
2
50% of the voting power of the Company's outstanding securities, (iii) there is
a replacement of more than one-half of the members of the Board of Directors
which is not approved by those individuals who are members of the Board of
Directors on the date thereof, or (iv) in one or a series of related
transactions, there is a sale or transfer of all or substantially all of the
assets of the Company, determined on a consolidated basis.
"Closing" means the closing of the purchase and sale of the
Shares and Warrant on the Closing Date.
"Closing Date" means 10 a.m., Dallas, Texas time, on September
__, 2003, or such other time or date as mutually agreed by the parties hereto.
"Closing Location" means ▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇,
▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇.
"Common Stock" means the Common Stock, $.001 per share, of the
Company.
"Common Stock Equivalent" means any warrant, option,
subscription or purchase right with respect to shares of Common Stock, any
security convertible into, exchangeable for, or otherwise entitling the holder
thereof to acquire, shares of Common Stock or any warrant, option, subscription
or purchase right with respect to any such convertible, exchangeable or other
security.
"Encumbrances" means all mortgages, deeds of trust, claims,
security interests, liens, pledges, leases, subleases, charges, escrows,
options, proxies, rights of occupancy, rights of first refusal, preemptive
rights, covenants, conditional limitations, hypothecations, prior assignments,
easements, title retention agreements, indentures, security agreements or any
other encumbrances of any kind.
"Environmental Law" shall have the meaning provided in Section
3.17.
"Excluded Shares" shall have the meaning provided in Section
6.3(b).
"Generally Accepted Accounting Principles" means, for any
Person, the United States generally accepted accounting principles and practices
applied by such Person from time to time in the preparation of its audited
financial statements.
"Intellectual Property" means all franchises, patents,
trademarks, service marks, tradenames (whether registered or unregistered),
copyrights, corporate names, licenses, trade secrets, proprietary software or
hardware, proprietary technology, technical information, discoveries, designs
and other proprietary rights, whether or not patentable, and confidential
information (including, without limitation, know-how, processes and technology)
used in the conduct of the business of the Company or any Subsidiary, or in
which the Company or any Subsidiary has an interest.
3
"Material Adverse Effect" means a material adverse effect on
the (i) business, properties, operations, condition (financial or other),
results of operations or prospects of the Company and the Subsidiaries, taken as
a whole; (ii) the validity or enforceability of, or the ability of the Company
to perform its obligations under, the Transaction Documents; or (iii) rights and
remedies of the Purchaser under the terms of the Transaction Documents.
"Nasdaq" means the Nasdaq National Market.
"Nasdaq Small Cap" means the Nasdaq Small Cap Market.
"1934 Act" means the Securities Exchange Act of 1934, as
amended, and the rules and regulations of the SEC promulgated thereunder.
"1933 Act" means the Securities Act of 1933, as amended, and
the rules and regulations of the SEC promulgated thereunder.
"NYSE" means the New York Stock Exchange, Inc.
"OTCBB" means the OTC Bulletin Board.
"Person" means an individual, corporation, partnership,
limited liability company, trust, business trust, association, joint stock
company, joint venture, pool, syndicate, sole proprietorship, unincorporated
organization, governmental authority or any other form of entity not
specifically listed herein.
"Purchase Price" means the amount shown on the signature pages
to this Agreement as the Purchaser's Purchase Price.
"Purchaser Share Notice" shall have the meaning provided in
Section 6.12.
"Registration Rights Agreement" means the Registration Rights
Agreement by and between the Company and the Purchaser in the form attached as
EXHIBIT C.
"Registration Statement" shall have the meaning provided in
the Registration Rights Agreement.
4
"Regulation D" means Regulation D adopted by the SEC under the
1933 Act.
"Restricted Ownership Percentage" shall have the meaning
provided in Section 6.3(b).
"SEC" means the U.S. Securities and Exchange Commission.
"SEC Filings" means the Company's Annual Report on Form 10-KSB
for the fiscal year ended December 31, 2002 and all other reports filed by the
Company pursuant to Section 13 or 15(d) of the 1934 Act since December 31, 2002.
"Securities" means the Shares, the Underlying Shares, the
Warrant and the Warrant Shares.
"Shares" means the shares of 7.5% Convertible Preferred Stock
of the Company being purchased by the Purchaser pursuant to this Agreement.
"Subsidiary" means any corporation or other entity of which a
majority of the capital stock or other ownership interests having ordinary
voting power to elect a majority of the board of directors or other persons
performing similar functions are at the time directly or indirectly owned by the
Company.
"Transaction Documents" means this Agreement, the Registration
Rights Agreement, the Certificate of Designation and the Warrant.
"20% Cap" shall have the meaning provided in Section 6.1(a).
"2002 10-K" means the Company's Annual Report on Form 10-KSB
for the fiscal year ended December 31, 2002, as filed as the SEC.
"Underlying Shares" means the shares of Common Stock issued or
issuable upon conversion of the Shares.
"Variable Rate Transaction" means a transaction in which the
Company issues or sells any Common Stock or Common Stock Equivalent (a) that is
convertible into, exchangeable or exercisable for, or includes the right to
receive additional shares of Common Stock either (x) at a conversion, exercise
or exchange rate or other price that is based upon and/or varies with the
trading prices of or quotations for the Common Stock at any time after the
initial issuance of such debt or equity securities, or (y) with a fixed
conversion, exercise, exchange or purchase price that is subject to being reset
at some future date after the initial issuance of Common Stock or Common Stock
5
Equivalent or upon the occurrence of specified or contingent events directly or
indirectly related to the business of the Company or the market for the Common
Stock (but excluding standard stock split, reverse stock split and stock
dividend anti-dilution provisions), or (b) pursuant to an "equity line"
structure which provides for the sale, from time to time, of securities of the
Company which are registered for sale or resale pursuant to the 1933 Act.
"Warrant" means the Company's Common Stock Purchase Warrant in
the form attached hereto as Exhibit B.
"Warrant Shares" means the shares of Common Stock issuable
upon exercise of or otherwise pursuant to the Warrant.
2. Purchases and Sales of the Shares and Warrant.
2.1 Purchase and Sale. Upon the terms and subject to the
conditions of this Agreement, the Purchaser hereby agrees to purchase from the
Company, and the Company hereby agrees to sell to the Purchaser, on the Closing
Date, the Shares and the Warrant for the Purchase Price. The Shares shall have
such powers, preferences and rights, and the qualifications, limitations or
restrictions thereof, as set forth in the Certificate of Designation in the form
attached hereto as Exhibit A, subject to the applicable terms and conditions of
this Agreement and the Registration Rights Agreement.
2.2 Payment. Payment by the Purchaser of the Purchase Price to
the Company at the Closing on the Closing Date shall be made as follows:
(a) the Purchaser shall pay to ▇▇▇▇▇▇ ▇. Garden, P.C. an
amount equal to $15,000 payable by the Company pursuant to Section 9.5, by wire
transfer of immediately available funds to an account designated by such firm;
(b) the Purchaser shall pay to ▇▇ ▇▇▇▇▇▇ & Company an amount
equal to $100,000 payable by the Company to such firm as a finder, by wire
transfer of immediately available funds to an account designated by such firm;
and
(c) Purchaser shall pay to the Company the balance of the
Purchase Price, after determination and deduction therefrom of the amounts to be
paid pursuant to Sections 2.2(a) and (b), by wire transfer of immediately
available funds to an account designated by the Company.
(d) For all purposes, upon payment of the amounts provided for
in this Section 2.2, the Purchaser shall be deemed to have paid the Purchase
Price in full to the Company and to have disbursed on behalf of the Company the
amounts provided in Sections 2.2(a) and (b). By agreeing to disburse funds on
behalf of the Company as provided in this Section 2.2, in no event shall the
Purchaser have any liability to any Person, including, without limitation, the
Persons identified in Sections 2.2(a) and (b), for payment or performance of any
obligation or liability of the Company to such Person.
6
2.3 Closing. The sale and purchase of the Shares and Warrant
shall occur on the Closing Date at the Closing Location. At the Closing on the
Closing Date, upon the terms and subject to the conditions of this Agreement,
(A) the Company shall issue and sell to the Purchaser the
Shares and the Warrant upon payment by the Purchaser to the Company of an amount
equal to the Purchase Price as provided in Section 2.2, and
(B) the Purchaser shall pay to the Company an amount equal to
the Purchase Price, as provided in Section 2.2, against issuance and sale by the
Company to the Purchaser of the Shares and Warrant.
3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company
hereby represents and warrants to, and covenants and agrees with, the Purchaser
that:
3.1 ORGANIZATION, GOOD STANDING AND QUALIFICATION. The Company
and each Subsidiary is a corporation duly incorporated, validly existing and
subsisting under the laws of the jurisdiction of its incorporation and has all
requisite corporate power and authority to carry on its business as now
conducted and to own its properties. The Company and each Subsidiary is duly
qualified to do business as a foreign corporation and is in good standing in
each jurisdiction in which the conduct of its business or its ownership or
leasing of property makes such qualification or licensing necessary unless the
failure to so qualify would not be reasonably likely to result in a Material
Adverse Effect. The Company has no Subsidiaries other than those listed in
Schedule 3.1 and has no investment in any other Person except such investments
as would be classified as current assets on a balance sheet of the Company,
prepared in accordance with Generally Accepted Accounting Principles.
3.2 AUTHORIZATION. The Company has full corporate power and
authority and has taken all requisite action on the part of the Company, its
officers, directors and stockholders necessary for (i) the authorization,
execution and delivery of the Transaction Documents, (ii) the authorization of
the performance of all obligations of the Company under the Transaction
Documents, and (iii) the authorization, issuance (or reservation for issuance)
and delivery of the Securities. The Transaction Documents constitute the legal,
valid and binding obligations of the Company, enforceable against the Company in
accordance with their terms, subject to bankruptcy, insolvency, reorganization,
moratorium and similar laws of general applicability, relating to or affecting
creditors' rights generally.
7
3.3 CAPITALIZATION. Set forth on Schedule 3.3 hereto is (a)
the authorized capital stock of the Company on the date hereof; (b) the number
of shares of capital stock issued and outstanding on the date hereof; (c) the
number of shares of capital stock issuable pursuant to the Company's stock
option, stock purchase, stock award and similar plans; and (d) the number of
shares of capital stock issuable and reserved for issuance pursuant to all
Common Stock Equivalents outstanding or which the Company has agreed to issue
(other than the Shares and the Warrant). All of the issued and outstanding
shares of the Company's capital stock have been duly authorized and validly
issued and are fully paid, nonassessable and free of preemptive rights. No
Person is entitled to preemptive or similar statutory or contractual rights with
respect to any securities of the Company. Except as set forth on Schedule 3.3 or
in the SEC Filings, there are no outstanding Common Stock Equivalents or other
rights, agreements or arrangements of any character under which the Company is
or may be obligated to issue any equity securities of any kind, and except as
contemplated by this Agreement, the Company is not currently in negotiations for
the issuance of any Common Stock Equivalents or capital stock of any kind. The
Company has no knowledge of any voting agreements, buy-sell agreements, option
or right of first purchase agreements or other agreements of any kind among any
of the security holders of the Company relating to the securities of the Company
held by them. Except as set forth on Schedule 3.3 and except for registration
statements currently on file, the Company has not granted any Person the right
(which is now outstanding or effective) to require the Company to register any
securities of the Company under the 1933 Act, whether on a demand basis or in
connection with the registration of securities of the Company for its own
account or for the account of any other Person.
3.4 VALID ISSUANCE. The aggregate number of shares of Common
Stock issued, outstanding and reserved for issuance is _______. The Company does
not have any obligation to issue shares of Common Stock for which it has not
reserved an adequate number of shares of Common Stock. The Shares and Warrant
are duly authorized, and such Securities, and the Underlying Shares issuable
upon conversion of the Shares and Warrant Shares issuable upon exercise of the
Warrant, have been duly authorized and when issued in accordance herewith and
with the terms of the Certificate of Designation and the Warrant, will be
validly issued, fully paid, non-assessable and free and clear of all
Encumbrances and restrictions, except for restrictions on transfer imposed by
applicable securities laws.
3.5 CONSENTS. The execution, delivery and performance by the
Company of the Transaction Documents and the offer, issuance and sale of the
Securities require no consent of, action by or in respect of, or filing with,
any Person, governmental body, agency, or official other than filings that have
been or will be made pursuant to applicable state securities laws and the
requirements of the OTCBB and other than the filing of a Form D by the Company
with the SEC, each of which the Company undertakes to file within the applicable
time periods.
8
3.6 DELIVERY OF SEC FILINGS; BUSINESS; NON-PUBLIC INFORMATION.
The Company has timely filed all material reports and other documents required
to be filed with the SEC pursuant to the 1934 Act since December 31, 1999. At
their respective times of filing with the SEC, the SEC Filings complied in all
material respects with the requirements of the 1934 Act and did not contain any
untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. The Company and the Subsidiaries are
engaged only in the business described in the SEC Filings, and the SEC Filings
contain a complete and accurate description of the business of the Company and
the Subsidiaries. The Company has not provided to the Purchaser (i) any
information required to be filed under the 1934 Act that has not been so filed
or (ii) any material non-public information concerning the Company and the
Subsidiaries.
3.7 USE OF PROCEEDS. The proceeds of the sale of the Shares
and the Warrant hereunder shall be used by the Company for working capital
purposes.
3.8 NO MATERIAL ADVERSE CHANGE. Since the filing of the 2002
10-K or as otherwise identified and described in the SEC Filings subsequently
filed by the Company with the SEC pursuant to the 1934 Act there has not been:
(i) any material change in the consolidated assets, liabilities,
financial condition or operating results of the Company and the
Subsidiaries from that reflected in the financial statements included
in the 2002 10-K, except changes in the ordinary course of business
which have not had, in the aggregate, a Material Adverse Effect;
(ii) any declaration or payment of any dividend, or any
authorization or payment of any distribution, on any of the capital
stock of the Company, or any redemption or repurchase of any
securities of the Company or any Subsidiary;
(iii) any material damage, destruction or loss, whether or not
covered by insurance, to any assets or properties of the Company or
any Subsidiary;
(iv) any waiver by the Company or any Subsidiary of a material
right or of a material debt owed to it which waiver is adverse to the
Company or any Subsidiary;
9
(v) any satisfaction or discharge of any Encumbrance or payment
of any obligation by the Company or any Subsidiary, except in the
ordinary course of business and which is not material to the assets,
properties, prospects, financial condition, operating results or
business of the Company and the Subsidiaries taken as a whole (as such
business is presently conducted and the Company has publicly disclosed
it is proposed to be conducted);
(vi) any material change or amendment to a material contract or
arrangement by which the Company or any Subsidiary or any of their
respective assets or properties is bound or subject;
(vii) any material labor difficulties or labor union organizing
activities with respect to employees of or contractors to the Company
or any Subsidiary;
(viii) any transaction entered into by the Company or any
Subsidiary other than in the ordinary course of business; or
(ix) any other event or condition of any character that may have
a Material Adverse Effect.
3.9 REGISTRATION STATEMENTS. During the preceding two years,
each registration statement and any amendment thereto filed by the Company
pursuant to the 1933 Act, as of the date such registration statement or
amendment became effective, complied as to form in all material respects with
the 1933 Act, and did not contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary in
order to make the statements made therein, in light of the circumstances under
which they were made, not misleading; and each prospectus or supplement filed
pursuant to Rule 424 under the 1933 Act, as of its issue date and as of the
closing of any sale of securities pursuant thereto did not contain any untrue
statement of a material fact or omit to state any material fact required to be
stated therein or necessary in order to make the statements made therein, in the
light of the circumstances under which they were made, not misleading.
3.10 FORM S-3 ELIGIBILITY. The Company is currently eligible
to register the resale of its Common Stock in a secondary offering on a
registration statement on Form S-3 under the 1933 Act and the Company shall
maintain such eligibility at least until the Registration Statement is ordered
effective by the SEC.
3.11 NO CONFLICT, BREACH, VIOLATION OR DEFAULT. (a) The
execution, delivery and performance of the Transaction Documents by the Company
and the issuance and sale of the Securities will not conflict with or result in
a breach or violation of any of the terms and provisions of, or constitute a
default under (i) the Company's Articles of Incorporation (including any
articles of amendment or articles designating series of shares) or the Company's
10
Bylaws, both currently in effect (copies of which have been provided to the
Purchaser before the date hereof) and as in effect on the date of issuance of
the Securities, (ii) any statute, rule, regulation or order of any governmental
agency or body or any court, domestic or foreign, having jurisdiction over the
Company or any Subsidiary or any of their respective assets or properties, or
(iii) any agreement or instrument to which the Company or any Subsidiary is a
party or by which the Company or any Subsidiary is bound or to which any of the
properties of the Company or any Subsidiary is subject.
(b) Except where it would not have a Material Adverse Effect,
the Company and each Subsidiary (i) is not in violation of any statute, rule or
regulation applicable to the Company or any Subsidiary or its assets, (ii) is
not in violation of any judgment, order or decree applicable to the Company or
any Subsidiary or any of their respective assets, and (iii) is not in breach or
violation of any agreement, note or instrument to which it or its assets are a
party or are bound or subject. To the best of the Company's knowledge, neither
the Company nor any Subsidiary has received notice from any Person of any claim
or investigation that, if adversely determined, would render the preceding
sentence untrue or incomplete.
3.12 TAX MATTERS. The Company and the Subsidiaries have timely
prepared and filed all tax returns required to have been filed by the Company
with all appropriate governmental agencies and timely paid all taxes owed by
them, except where failure to make such payment would not have a Material
Adverse Effect. The charges, accruals and reserves on the books of the Company
and the Subsidiaries in respect of taxes for all fiscal periods are adequate in
all material respects, and there are no material unpaid assessments against the
Company or any Subsidiary nor, to the knowledge of the Company, any basis for
the assessment of any additional taxes, penalties or interest for any fiscal
period or audits by any foreign, U.S. federal, state, representations or
warranties in or local taxing authority, except such as are not material. All
material taxes and other assessments and levies that the Company or any
Subsidiary is required to withhold or to collect for payment have been duly
withheld and collected and paid to the proper governmental entity or third party
when due. There are no tax liens or claims pending or threatened against the
Company or any Subsidiary or any of their respective assets or property which if
adversely decided, would have a Material Adverse Effect. There are no
outstanding tax sharing agreements or other such arrangements between the
Company or any Subsidiary and any other Person.
3.13 TITLE TO PROPERTIES. Except as disclosed in the SEC
Filings, the Company and each Subsidiary has good and marketable title to all
real properties and all other properties and assets owned by it, in each case
free from Encumbrances and defects that would materially affect the value
thereof or materially interfere with the use made or currently planned to be
made thereof by the Company or such Subsidiary; and except as disclosed in the
SEC Filings, the Company and each Subsidiary holds any leased real or personal
property under valid and enforceable leases with no exceptions that would
materially interfere with the use made or currently planned to be made thereof
by the Company or such Subsidiary.
11
3.14 CERTIFICATES, LICENSES, AUTHORIZATIONS AND PERMITS. The
Company and each Subsidiary possesses adequate certificates, licenses,
authorizations or permits issued by appropriate governmental agencies or bodies
necessary to conduct the business now operated by it and has not received any
notice of proceedings relating to the revocation or modification of any such
certificate, license, authorization or permit that, if determined adversely to
the Company or any Subsidiary, would individually or in the aggregate have a
Material Adverse Effect.
3.15 NO LABOR DISPUTES. No material labor dispute with the
employees of or contractors to the Company or any Subsidiary exists or, to the
knowledge of the Company, is imminent.
3.16 INTELLECTUAL PROPERTY. (1) The Company and each
Subsidiary holds all Intellectual Property, free and clear of all Encumbrances
and restrictions on use or transfer, whether or not recorded, and has sole title
to and ownership of or has the full, exclusive (subject to the rights of its
licensees or licensors) right to use in its field of business, for the life of
the proprietary right all Intellectual Property; (2) the use of the Intellectual
Property by the Company or any Subsidiary does not, to the knowledge of the
Company after due inquiry, violate or infringe on the rights of any other
Person; (3) neither the Company nor any Subsidiary has received any notice of
any conflict between the asserted rights of others and the Company or any
Subsidiary with respect to any Intellectual Property; (4) the Company and each
Subsidiary has used its best efforts to perfect its rights in and to all
Intellectual Property used by it in its business or in which it has an interest;
(5) the Company and each Subsidiary are in compliance with all material terms
and conditions of its agreements relating to the Intellectual Property; (6)
neither the Company nor any Subsidiary is or has been a defendant in any action,
suit, investigation or proceeding relating to infringement or misappropriation
by the Company or any Subsidiary of any Intellectual Property; (7) neither the
Company nor any Subsidiary has been notified of any alleged claim of
infringement or misappropriation by the Company or any Subsidiary of any
Intellectual Property; (8) the Company has no knowledge of any claim of
infringement or misappropriation by the Company or any Subsidiary of any
Intellectual Property; (9) to the knowledge (after due inquiry) of the Company,
none of the products the Company and the Subsidiaries are researching,
developing, propose to research and develop, make, have made, use, or sell,
infringes or misappropriates any Intellectual Property right of any third party;
(10) none of the trademarks and service marks used by the Company or any
Subsidiary, to the knowledge of the Company after due inquiry, infringes the
trademark or service ▇▇▇▇ rights of any third party; (11) to the Company's
knowledge none of the material processes and formulae, research and development
results and other know-how relating to the Company's or the Subsidiaries'
12
respective businesses, the value of which to the Company or any Subsidiary is
contingent upon maintenance of the confidentiality thereof, has been disclosed
to any Person other than Persons bound by written confidentiality agreements;
and (12) the Company owns directly, or possesses adequate rights to use, all
Intellectual Property used in or relating to the development, manufacture, use,
distribution or marketing of the Company's products, and none of such
Intellectual Property is owned, claimed or used by, or subject to any
Encumbrance of or by, any Subsidiary.
3.17 ENVIRONMENTAL MATTERS. Neither the Company nor any
Subsidiary is in violation of any statute, rule, regulation, decision or order
of any governmental agency or body or any court, domestic or foreign, relating
to the use, disposal or release of hazardous or toxic substances or relating to
the protection or restoration of the environment or human exposure to hazardous
or toxic substances (collectively, "Environmental Laws"), does not own or
operate any real property contaminated with any substance that is subject to any
Environmental Laws, is not liable for any off-site disposal or contamination
pursuant to any Environmental Laws, and is not subject to any claim relating to
any Environmental Laws, which violation, contamination, liability or claim would
individually or in the aggregate have a Material Adverse Effect; and neither the
Company nor any Subsidiary is aware of any pending investigation that might lead
to such a claim.
3.18 LITIGATION. Except as set forth in the SEC Filings, there
are no pending actions, suits or proceedings against or affecting the Company or
any Subsidiary or any of their respective properties that, if determined
adversely to the Company or such Subsidiary, would individually or in the
aggregate have a Material Adverse Effect, or which are otherwise material in the
context of the sale of the Securities; and to the Company's knowledge, no such
actions, suits or proceedings are threatened or contemplated.
3.19 FINANCIAL STATEMENTS. The consolidated financial
statements included in each SEC Filing present fairly and accurately in all
material respects the consolidated financial position of the Company and the
Subsidiaries as of the dates reported and the consolidated results of
operations, changes in stockholders' equity and cash flows for the periods
reported, all in conformity with Generally Accepted Accounting Principles
applied on a consistent basis and in conformity with the rules and regulations
of the SEC under the 1934 Act applicable to the Company. Except as set forth in
the consolidated financial statements of the Company included in the SEC Filings
filed prior to the date hereof, neither the Company nor any Subsidiary has any
liabilities, contingent or otherwise, except those which individually or in the
aggregate are not material to the financial condition or operating results of
the Company and the Subsidiaries, taken as a whole.
13
3.20 INSURANCE COVERAGE. The Company and each Subsidiary
maintains in full force and effect insurance coverage that is customary for
comparably situated companies for the business being conducted and properties
owned or leased by it, and the Company reasonably believes such insurance
coverage to be adequate against all liabilities, claims and risks against which
it is customary for comparably situated companies to insure.
3.21 ▇▇▇▇▇▇▇▇-▇▇▇▇▇. The Company is in compliance with any and
all applicable requirements of the ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act of 2002 that are effective
as of the date hereof, and any and all applicable rules and regulations
promulgated by the SEC thereunder that are effective as of the date hereof,
except where such noncompliance would not have, individually or in the
aggregate, a Material Adverse Effect.
3.22 ACKNOWLEDGEMENT OF POTENTIAL DILUTION. The Company
understands that the number of shares of Common Stock issuable upon conversion
of the Shares and exercise of the Warrant may increase substantially and that
such increase may have a dilutive effect on the Company's equity capitalization.
3.23 BROKERS AND FINDERS. The Purchaser shall have no
liability or responsibility for the payment of any commission or finder's fee to
any third party in connection with or resulting from this Agreement or the
transactions contemplated by this Agreement by reason of any agreement of or
action taken by the Company.
3.24 NO DIRECTED SELLING EFFORTS OR GENERAL SOLICITATION.
Notwithstanding anything contained on any schedule hereto, neither the Company
nor any Person acting on its behalf has conducted any general solicitation or
general advertising (as those terms are used in Regulation D) in connection with
the offer or sale of any of the Securities.
3.25 NO INTEGRATED OFFERING. Neither the Company nor any of
its Affiliates, nor any Person acting on its or their behalf has, directly or
indirectly, made any offers or sales of any security or solicited any offers to
buy any security, under circumstances that would (1) adversely affect reliance
by the Company on Section 4(2) of the 1933 Act for the exemption from
registration for the transactions contemplated hereby or would require
registration of the offer and sale of the Shares and Warrant to the Purchaser
under the 1933 Act; or (2) require the integration of the offering of the
Securities with any other offering of securities for purposes of determining the
need to obtain stockholder approval of the transactions contemplated hereby
under the rules of the OTCBB.
14
3.26 DISCLOSURES. For purposes of this Agreement and the
transactions contemplated hereby, none of the representations or warranties made
by the Company under any of the Transaction Documents and no written information
furnished by the Company pursuant hereto, or in any other document, certificate
or written statement furnished by the Company to the Purchaser or any authorized
representative of the Purchaser, pursuant to the Transaction Documents or in
connection therewith, contains any untrue statement of a material fact or omits
to state a material fact necessary in order to make the statements contained
herein and therein, in light of the circumstances under which they were made,
not misleading.
3.27 ABSENCE OF RIGHTS AGREEMENT. The Company has not adopted
a shareholder rights plan or similar arrangement relating to accumulations of
beneficial ownership of Common Stock or a change of control in the Company.
4. REPRESENTATIONS AND WARRANTIES OF THE PURCHASER. The
Purchaser hereby represents and warrants to the Company that:
4.1 ORGANIZATION AND EXISTENCE. Such Purchaser is a validly
existing partnership and has all requisite partnership power and authority to
invest in the Securities pursuant to this Agreement.
4.2 PURCHASE ENTIRELY FOR OWN ACCOUNT. The Securities to be
acquired by the Purchaser pursuant to this Agreement will be acquired for the
Purchaser's own account, not as nominee or agent, and not with a view to the
resale or distribution of any part thereof in violation of applicable securities
laws, and the Purchaser has no present intention of selling, granting any
participation in, or otherwise distributing the same in violation of applicable
securities laws.
4.3 INVESTMENT EXPERIENCE. The Purchaser acknowledges that it
can bear the economic risk and complete loss of its investment in the Securities
and has such knowledge of and experience with securities and financial or
business matters that it is capable of evaluating the merits and risks of the
purchase of the Shares and Warrant.
4.4 DISCLOSURE OF INFORMATION. The Purchaser has had an
opportunity to review documents related to the Company and to ask questions of
and receive answers from the Company regarding the terms and conditions of the
offering of the Securities; provided however, that neither such inquiries nor
any other investigation conducted by the Purchaser shall modify, amend, limit or
otherwise affect the Purchaser's right to rely on the Company's representations
and warranties contained in the Transaction Documents or made pursuant to the
Transaction Documents.
15
4.5 RESTRICTED SECURITIES. The Purchaser understands that the
Shares and Warrant are characterized as "restricted securities" under the U.S.
federal securities laws inasmuch as they are being acquired from the Company in
a transaction not involving a public offering and that under such laws and
applicable regulations such securities may be resold without registration under
the 1933 Act only in certain limited circumstances.
4.6 ACCREDITED INVESTOR. The Purchaser is an "accredited
investor" as defined in Rule 501(a) of Regulation D.
4.7 NO GENERAL SOLICITATION. The Purchaser did not learn of
the offering of the Shares and Warrant through any public advertising or general
solicitation (as these terms are used in Regulation D).
4.8 RESIDENCY OF PURCHASER. The Purchaser is a resident of the
state or other jurisdiction indicated in the first paragraph of this Agreement.
4.9 BROKERS AND FINDERS. The Company shall have no liability
or responsibility for the payment of any commission or finder's fee to any third
party in connection with or resulting from this Agreement or the transactions
contemplated by this Agreement by reason of any agreement of the Purchaser.
4.10 AUTHORIZATION. The Purchaser has full partnership power
and authority and has taken all requisite action on the part of the Purchaser
and its partners necessary for (i) the authorization, execution and delivery of
the Transaction Documents and (ii) the authorization of the performance of all
obligations of the Purchaser under the Transaction Documents. The Transaction
Documents constitute the legal, valid and binding obligations of the Purchaser,
enforceable against the Purchaser in accordance with their terms, subject to
bankruptcy, insolvency, reorganization, moratorium and similar laws of general
applicability, relating to or affecting creditors' rights generally.
4.11 RISK FACTORS. Without limiting any of the Purchaser's
other representations and warranties hereunder, the Purchaser acknowledges that
the Purchaser has reviewed and is aware of the risk factors described in the SEC
Filings.
4.12 RELIANCE. The Purchaser has consulted its own financial,
legal and tax advisors with respect to the economic, legal and tax consequences
of an investment in the Shares and Warrant and has not relied on the SEC Filings
or the Company, its officers, directors or professional advisors as to such
consequences.
4.13 NO REPRESENTATIONS. No oral representations have been
made by the Company to the Purchaser in connection with the Transaction
Documents; and no written representations have been made by the Company to the
Purchaser other than as stated in the Transaction Documents and the SEC Filings.
4.14 SURVIVAL. The Purchaser acknowledges that the
representations, warranties and agreements made by the Purchaser herein shall
survive the execution and delivery of this Agreement and the purchase of the
Shares and Warrant.
16
5. REGISTRATION RIGHTS AGREEMENT.
5.1 REGISTRATION RIGHTS AGREEMENT. The Company acknowledges
and agrees that the Company's execution and delivery of, and full performance of
its obligations under, the Registration Rights Agreement is a material
inducement to the Purchaser to execute and deliver this Agreement and purchase
and pay for the Shares and Warrant. The Company agrees to execute and deliver to
the Purchaser the Registration Rights Agreement at or before the Closing.
6. CERTAIN COVENANTS OF THE COMPANY AND THE PURCHASER.
6.1 19.99% CAP; RULE 144.
(a) 19.99% CAP. Notwithstanding anything contained herein or
in the other Transaction Documents, if Rule 4350(i)(1)(D) of the Nasdaq is
applicable the Company shall not be entitled to issue upon conversion of the
Shares and exercise of the Warrant an aggregate number of shares of Common Stock
in excess of 19.99% of the Common Stock issued and outstanding on the date
hereof, subject to appropriate and equitable adjustment for any stock split,
stock dividend or reclassification of the Common Stock or similar event
occurring after the date hereof (the "20% Cap"), unless the Company receives
stockholder approval for such issuance. If Rule 4350(i)(1)(D) of the Nasdaq is
applicable to the shares of Common Stock issuable upon conversion of the Shares
and exercise of the Warrant and the limitations thereof restrict the Company
from issuing additional shares of Common Stock upon conversion of the Shares or
exercise of the Warrant, then the Company shall use its commercially reasonable
best efforts to obtain, as promptly as practicable, but in no event later than
120 days thereafter, the stockholder approval that is necessary under the rules
of the Nasdaq so that the 20% Cap would no longer be applicable to issuance of
shares of Common Stock upon conversion of the Shares and exercise of the
Warrant.
(b) Rule 144. The Company acknowledges that, for purposes of
determining the holding period under Rule 144 for Underlying Shares issued upon
conversion of the Shares, the holding period of such Underlying Shares shall be
tacked to the holding period of the Shares and for purposes of determining the
holding period under Rule 144 for Warrant Shares issued in a "net" or "cashless"
exercise of the Warrant, the holding period of such Warrant Shares may be tacked
to the holding period of the Warrant. The Company agrees not to take a position
contrary thereto unless the SEC or its staff by rule or interpretation changes
its rules and interpretations thereof in effect on the date of this Agreement or
such rules or interpretations are held invalid or incorrect by a court of
competent jurisdiction.
17
6.2 LIMITATION ON CERTAIN TRANSACTIONS.
(a) Beginning as of the date of this Agreement and until the
effective date of the Registration Statement as contemplated by the Registration
Rights Agreement, without the prior written consent of the Purchaser (which
consent may be withheld in the Purchaser's discretion), the Company shall not
issue or sell or agree to issue or sell any securities in a capital raising
transaction prior to such date, unless such securities will not be, and are not,
registered for sale or resale under the 1933 Act until on or after the effective
date of the Registration Statement, provided that the limitation of this Section
6.2(a) shall not apply to securities issued pursuant to the Company's duly
adopted employee or director bona fide share and option plans.
(b) So long as any of the Shares remain outstanding, without
the prior written consent of holders owning more than 50% of the Shares (which
consent may be withheld in such holders' discretion), the Company shall not
issue or sell, or agree to issue or sell, any securities in a Variable Rate
Transaction.
6.3 RIGHT OF THE PURCHASER TO PARTICIPATE IN FUTURE
TRANSACTIONS.
(a) RIGHT TO PARTICIPATE. So long as any of the Shares remain
outstanding, the Purchaser will have a right to participate in any sales of any
of the Company's securities in a capital raising transaction on the terms and
conditions set forth in this Section 6.3. During such period, the Company shall
give ten Business Days advance written notice to the Purchaser prior to any
non-public offer or sale of any of the Company's capital stock or any Common
Stock Equivalents in a capital raising transaction by providing to the Purchaser
a comprehensive term sheet containing all significant business terms of such a
proposed transaction. The Purchaser shall have the right to participate in such
proposed transaction and to purchase 25 percent of such securities which are the
subject of such proposed transaction for the same consideration and on the same
terms and conditions as contemplated for such third-party sale (or such lesser
portion thereof as specified by the Purchaser). If the Purchaser elects to
exercise its rights hereunder it must deliver written notice to the Company
within five (5) Business Days following receipt of the notice and comprehensive
18
term sheet from the Company, which notice from the Purchaser shall be contingent
upon receipt of satisfactory definitive documents for such transaction from the
Company. If, subsequent to the Company giving notice to the Purchaser hereunder
but prior to the Purchaser exercising its right to participate (or the
expiration of the five-day period without response from the Purchaser or the
rejection of such offer for such financing by the Purchaser), the terms and
conditions of the proposed third-party sale are changed from that disclosed in
the comprehensive term sheet provided to the Purchaser, the Company shall be
required to provide a new notice and comprehensive term sheet reflecting such
revised terms to the Purchaser hereunder and the Purchaser shall have the right,
which must be exercised within five (5) Business Days of such new notice and
such revised comprehensive term sheet, to exercise its rights to purchase the
securities on such changed terms and conditions as provided hereunder. In the
event the Purchaser does not exercise its rights hereunder with respect to a
proposed transaction within the period or periods provided, or affirmatively
declines to engage in such proposed transaction with the Company, then the
Company may proceed with such proposed transaction on the same terms and
conditions as noticed to the Purchaser (assuming the Purchaser has consented to
the transaction, if required, pursuant to Section 6.2 of this Agreement) with
the Purchaser if it has elected to participate in such proposed transaction,
provided that if such proposed transaction is not consummated within 60 days
following the Company's notice hereunder, then the right of first refusal
hereunder shall again apply to the Purchaser for such proposed transaction. The
rights and obligations under this Section 6.3 shall in no way diminish the other
rights of the Purchaser pursuant to this Section 6.
(b) LIMITATION ON RIGHT OF FIRST REFUSAL. Notwithstanding
anything to the contrary contained herein, the number of shares of Common Stock
that may be acquired directly or through acquisition of Common Stock Equivalents
by the Purchaser pursuant to any capital raising transaction as described in
subsection (a) above shall not exceed a number that, when added to the total
number of shares of Common Stock deemed beneficially owned by the Purchaser
(other than by virtue of the ownership of securities or rights to acquire
securities (including the Shares and Warrant) that have limitations on the
Purchaser's right to convert, exercise or purchase similar to the limitation set
forth herein (the "Excluded Shares")), together with all shares of Common Stock
deemed beneficially owned (not counting such affiliate's Excluded Shares) by the
19
Purchaser (as defined in Rule 144 of the 1933 Act) (the "Aggregation Parties")
that would be aggregated for purposes of determining whether such securities are
beneficially owned by the Purchaser or for purposes of determining whether a
group exists, in each such case for purposes of Section 13(d) of the 1934 Act
and Regulation 13D-G thereunder, would result in beneficial ownership by the
Purchaser or such group of more than 9.9% of the shares of the Company's Common
Stock (the "Restricted Ownership Percentage"), computed in accordance with
Regulation 13D-G. The Purchaser shall have the right at any time and from time
to time to reduce its Restricted Ownership Percentage immediately upon notice to
the Company in the event and only to the extent that Section 16 of the 1934 Act
or the rules promulgated thereunder (or any successor statute or rules) is
changed to reduce the beneficial ownership percentage threshold thereunder from
10%. If the Purchaser is unable by reason of the Restricted Ownership Percentage
to acquire the full amount of securities which the Purchaser would otherwise be
entitled to acquire pursuant to this Section 6.3 and thereafter, at any time
prior to the conversion in full of the Shares the Purchaser could acquire such
securities without exceeding its Restricted Ownership Percentage, then the
Purchaser shall be entitled to acquire such securities at such time.
6.4 REPORTS AND INFORMATION. For so long as the Purchaser
beneficially owns any of the Securities, the Company will furnish to the
Purchaser the following reports and information, each of which shall be provided
to the Purchaser by e-mail (at such address as specified in writing by the
Purchaser for such purpose) or reputable overnight courier:
(a) QUARTERLY FINANCIAL INFORMATION. In the absence of a
Quarterly Report on Form 10-Q timely filed with the SEC for any of the Company's
first three fiscal quarters in any fiscal year, within 45 days after the end of
any such fiscal quarter consolidated balance sheets of the Company as at the end
of each of the Company's first three fiscal quarters and the related
consolidated statements of operations, stockholders' equity and cash flows for
such period and for the portion of the Company's fiscal year ended on the last
day of such quarter, all in reasonable detail and certified by the principal
financial officer of the Company to have been prepared in accordance with
Generally Accepted Accounting Principles, subject to year-end and audit
adjustments.
(b) ANNUAL FINANCIAL INFORMATION. In the absence of a Form
10-K timely filed with the SEC within 105 days after the end of any fiscal year,
then within such period consolidated balance sheets of the Company as at the end
of each fiscal year and the related consolidated statements of earnings,
stockholders' equity and cash flows for such year, all in reasonable detail and
accompanied by the report on such consolidated financial statements of an
independent certified public accountant selected by the Company and reasonably
satisfactory to the Purchaser.
(c) STOCKHOLDER AND ANALYST REPORTS AND INFORMATION. Copies of
all notices, financial statements, reports and documents as the Company shall
send or make available generally to its stockholders or to financial analysts,
promptly after providing same to the stockholders or financial analysts.
20
(d) OTHER INFORMATION. Such other information relating to the
Company and the Subsidiaries as from time to time may reasonably be requested by
the Purchaser provided the Company or its Subsidiary has such information
available to it in the ordinary course of its business, and further provided
that the Company, solely in its own discretion, determines that such information
is not confidential in nature and disclosure to such Purchaser would not be
harmful to the Company or its Subsidiary.
Notwithstanding anything to the contrary contained in this Section 6.4, the
Company shall not disclose material nonpublic information to the Purchaser, or
to advisors to or representatives of the Purchaser, unless prior to disclosure
of such information the Company identifies such information as being material
nonpublic information and provides the Purchaser, such advisors and
representatives with the opportunity to accept or refuse to accept such material
nonpublic information for review. The Company may, as a condition to disclosing
any material nonpublic information hereunder, require the Purchaser's advisors
and representatives to enter into a confidentiality agreement (including an
agreement with such advisors and representatives prohibiting them from trading
in Common Stock during such period of time as they are in possession of material
nonpublic information) in form reasonably satisfactory to the Company and the
Purchaser.
(e) RULE 144. The Company agrees to make publicly available on
a timely basis the information required by Rule 144(c) under the 1933 Act.
6.5 PRESS RELEASES. Any press release or other publicity
concerning this Agreement or the transactions contemplated by this Agreement
shall be submitted to the Purchaser for comment at least two (2) Business Days
prior to issuance, unless the release is required to be issued within a shorter
period of time by law or pursuant to the rules of any Approved Market (if
applicable). The Company shall, on the Closing Date, issue a press release
concerning the transactions contemplated hereby. The Company's other press
releases and other public information, to the extent concerning the Transaction
Documents, shall contain such information as reasonably requested by the
Purchaser and be reasonably approved by the Purchaser in writing prior to
issuance.
6.6 NO CONFLICTING AGREEMENTS. The Company will not take any
action, enter into any agreement or make any commitment that would conflict or
interfere in any material respect with the obligations to the Purchaser under
the Transaction Documents.
21
6.7 INSURANCE. For so long as the Purchaser beneficially owns
any of the Securities, the Company shall, and shall cause each Subsidiary to,
have in full force and effect (a) insurance reasonably believed to be adequate
on all assets and activities of a type customarily insured, covering property
damage and loss of income by fire or other casualty, and (b) insurance
reasonably believed to be adequate protection against all liabilities, claims
and risks against which it is customary for companies similarly situated as the
Company and the Subsidiaries to insure.
6.8 COMPLIANCE WITH LAWS. So long as the Purchaser
beneficially owns any Securities, the Company will use reasonable efforts to
comply with all applicable laws, rules, regulations, orders and decrees of all
governmental authorities, except to the extent non-compliance (in one instance
or in the aggregate) would not have a Material Adverse Effect.
6.9 LISTING OF UNDERLYING SHARES AND WARRANT SHARES AND
RELATED MATTERS. The Company agrees that if the Company applies to have its
Common Stock or other securities traded on any other principal stock exchange or
market, it will include in such application the Underlying Shares and Warrant
Shares and will take such other action as is necessary to cause such Common
Stock to be so listed. For so long as any Shares or the Warrant remain
outstanding, the Company will take all action necessary to continue the listing
and trading of its Common Stock on at least one of the OTC Bulletin Board, the
Nasdaq Small Cap, the Nasdaq, the NYSE or the AMEX (collectively, "Approved
Markets"), and will comply in all respects with the Company's reporting, filing
and other obligations under the bylaws or rules of such exchange or market, as
applicable, to ensure the continued eligibility for trading of the Common Stock
thereon. Neither the Company nor any of its Affiliates, nor any Person acting on
its or their behalf, shall directly or indirectly make any offers or sales of
any security or solicit any offers to buy any security which may cause the
integration of the offering hereunder with any other offering of securities for
purposes of determining the need to obtain stockholder approval of the
transactions contemplated hereby under any applicable rules of any Approved
Market. Unless in its reasonable judgment such would constitute material
non-public information, the Company shall notify the Purchaser in advance if it
intends to make any private placement of securities within the six-month period
after the Closing Date, and unless the Company shall have received stockholder
approval of the transactions contemplated hereby under the rules of any Approved
Market (if applicable), at the Purchaser's reasonable request, the Company shall
request a ruling from such Approved Market in advance that such private
placement will not be integrated with the transactions contemplated hereunder
pursuant to the rules of such Approved Market.
6.10 Corporate Existence. So long as any Shares or the Warrant
remain outstanding, the Company shall maintain its corporate existence, except
in the event of a merger, consolidation, amalgamation or sale of all or
substantially all of the Company's assets, as long as the surviving or successor
entity in such transaction (a) assumes (jointly and severally with the Company
if the Company continues to exist) the Company's obligations hereunder and under
the agreements and instruments entered into in connection herewith, regardless
of whether or not the Company would have had a sufficient number of shares of
22
Common Stock authorized and available for issuance in order to fulfill its
obligations hereunder and effect the conversion in full of all Shares and
exercise in full of all Warrants outstanding as of the date of such transaction;
(b) has no legal, contractual or other restrictions on its ability to perform
the obligations of the Company hereunder and under the agreements and
instruments entered into in connection herewith; and (c)(i) is a publicly traded
corporation whose common stock and the shares of capital stock issuable upon
conversion of the Shares and exercise of the Warrant are (or would be upon
issuance thereof) listed for trading on an Approved Market or (ii) if not such a
publicly traded corporation, then the Person who will be the successor or
surviving entity in such transaction, at the time it shall enter into a
definitive agreement to complete such transaction, shall have agreed in writing
with the Purchaser that it will, at the election of the Purchaser, purchase the
Purchaser's Securities at a price equal to the greater of (a) 120% of the
Purchase Price of such Securities or (b) the fair market value of such
Securities on an as-converted and as-exercised basis based on the closing price
immediately preceding such transaction or the redemption date, whichever is
greater.
6.11 FORM 8-K. Within one Business Day after the Closing Date,
the Company will publicly report the issue and sale of the Shares and Warrant by
filing with the SEC a Current Report on Form 8-K under the 1934 Act which report
shall describe the material terms and include copies of the Transaction
Documents as exhibits to such report.
6.12 LEGENDS. Until registration for resale pursuant to the
Registration Rights Agreement or until sales under Rule 144 under the 1933 Act
are permitted, certificates evidencing the Underlying Shares and the Warrant
Shares may bear one or both of the following legends or legends substantially
similar thereto:
(a) "The shares represented by this certificate may not be transferred
without (i) the opinion of counsel reasonably satisfactory to the
corporation that such transfer may lawfully be made without
registration under the Securities Act of 1933 or qualification under
applicable state securities laws; or (ii) such registration or
qualification."
(b) If required by the authorities of any state in connection with the
issuance of sale of the Securities, the legend required by such state.
Upon registration for resale pursuant to the Registration Rights Agreement or
upon Rule 144(k) under the 1933 Act becoming available, the Company shall
promptly (but in no event later than five Business Days after surrender of the
legended certificates to the Company) cause certificates evidencing the
Underlying Shares and Warrant Shares previously issued to be replaced with
certificates which do not bear the restrictive legends set forth in the
preceding clause (a) of this Section, and all Underlying Shares and Warrant
23
Shares subsequently issued shall not bear the restrictive legend set forth in
the preceding clause (a) of this Section. If the Purchaser notifies the Company
that the Purchaser has not received such certificates without the restrictive
legend set forth in the preceding clause (a) of this Section within three
Business Days after surrender of such legended certificates (each, a "Purchaser
Share Notice"), and the Purchaser does not receive such certificates without the
restrictive legend set forth in the preceding clause (a) of this Section within
two Business Days after giving a particular Purchaser Share Notice, then the
Company shall pay cash liquidated damages to the Purchaser at the rate of 2% per
month of the original Purchase Price of the Shares and Warrant in respect of
which such Underlying Shares and Warrant Shares are issuable or issued and for
which the certificates have not been provided in compliance with the above, for
so long as the Company fails to provide such certificates. A Purchaser Share
Notice may be given by telephone or e-mail to the Company's Chief Financial
Officer or General Counsel. The Purchaser agrees that any sale by the Purchaser
of Underlying Shares and Warrant Shares pursuant to the Registration Statement
shall be made by the Purchaser in compliance with the prospectus delivery
requirements of the 1933 Act and in accordance with the plan of distribution set
forth in the Registration Statement and related prospectus, as amended and
supplemented from time to time.
7. CONDITIONS TO THE COMPANY'S OBLIGATIONS TO ISSUE AND SELL.
The Company's obligation to issue and sell the Shares and Warrant to the
Purchaser pursuant to this Agreement is conditioned upon satisfaction of the
following conditions precedent on or before the Closing Date (any or all of
which may be waived by the Company in its sole discretion):
(a) On the Closing Date, no legal action, suit or proceeding
shall be pending or threatened which seeks to restrain or prohibit the
transactions contemplated by this Agreement; and
(b) The representations and warranties of the Purchaser
contained in this Agreement shall have been true and correct on the date of this
Agreement and the representations and warranties of the Purchaser contained in
the Transaction Documents shall be true and correct on the Closing Date as if
given on and as of the Closing Date (except for representations given as of a
specific date, which representations shall be true and correct as of such date),
and on or before the Closing Date the Purchaser shall have performed all
covenants and agreements of the Purchaser contained herein or in any of the
other Transaction Documents required to be performed by the Purchaser on or
before the Closing Date.
8. CONDITIONS TO THE PURCHASER'S OBLIGATIONS TO PURCHASE. The
Purchaser's obligations to purchase the Shares and Warrant are conditioned upon
satisfaction of the following conditions precedent on or before the Closing Date
(any or all of which may be waived by the Purchaser in its sole discretion):
24
(a) On the Closing Date, no legal action, suit or proceeding
shall be pending or threatened which seeks to restrain or prohibit the
transactions contemplated by this Agreement;
(b) The representations and warranties of the Company
contained in this Agreement shall have been true and correct on the date of this
Agreement and the representations and warranties of the Company contained in the
Transaction Documents shall be true and correct on the Closing Date as if given
on and as of the Closing Date (except for representations given as of a specific
date, which representations shall be true and correct as of such date), and on
or before the Closing Date the Company shall have performed all covenants and
agreements of the Company contained herein or in any of the other Transaction
Documents required to be performed by the Company on or before the Closing Date;
(c) No Change in Control Transaction shall have occurred;
(d) The Company shall have delivered to the Purchaser a
certificate, dated the Closing Date, duly executed by its Chief Executive
Officer or Chief Financial Officer, to the effect set forth in subparagraphs
(a), (b) and (c) of this Section 8;
(e) The Company shall have delivered to the Purchaser a
certificate, dated the Closing Date, of the Secretary of the Company certifying
(A) the Certificate of Incorporation and By-Laws of the Company as in effect on
the Closing Date, (B) all resolutions of the Board of Directors (and committees
thereof) of the Company relating to this Agreement and the other Transaction
Documents and the transactions contemplated hereby and thereby, and (C) such
other matters as reasonably requested by the Purchaser;
(f) As of the Closing Date, the Company shall have filed with
the Nevada Secretary of State the Certificate of Designation authorizing the
Shares in substantially the Form of Exhibit A attached hereto; and
(g) On the Closing Date, (i) trading in securities on the
OTCBB shall not have been suspended or materially limited and (ii) a general
moratorium on commercial banking activities in the State of Texas shall not have
been declared by either federal or state authorities, nor shall there have
occurred any material outbreak or escalation of hostilities or other national or
international calamity or crisis of such magnitude in its effect on, or any
material adverse change in any financial market which, in each case, in the good
faith judgment of the Purchaser, makes it impracticable or inadvisable to
purchase the Shares and Warrant.
25
9. MISCELLANEOUS.
9.1 SUCCESSORS AND ASSIGNS. This Agreement may not be assigned
by the Company. This Agreement may not be assigned by the Purchaser prior to the
Closing without the prior written consent of the Company, which consent may not
be unreasonably withheld, conditioned or delayed, except that after the Closing,
without the prior written consent of the Company, but after notice given to the
Company, the Purchaser may assign its rights and delegate its duties hereunder
in whole or in part to an Affiliate or to any transferee of Securities from the
Purchaser. The terms and conditions of this Agreement shall inure to the benefit
of and be binding upon the respective successors and permitted assigns of the
parties. Nothing in this Agreement, express or implied, is intended to confer
upon any party other than the parties hereto or their respective successors and
permitted assigns any rights, remedies, obligations, or liabilities under or by
reason of this Agreement, except as expressly provided in this Agreement.
9.2 COUNTERPARTS. This Agreement may be executed in two or
more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
9.3 TITLES AND SUBTITLES. The titles and subtitles used in
this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.
9.4 NOTICES. Unless otherwise provided, any notice required or
permitted under this Agreement shall be given in writing and shall be deemed
effectively given only upon delivery to each party to be notified by (i)
personal delivery, (ii) telephone line facsimile transmission, upon receipt of
confirmation of complete transmittal, or (iii) a recognized overnight air
courier, addressed to the party to be notified at the address as follows, or at
such other address as such party may designate by ten days' advance written
notice to the other party:
If to the Company:
Biogentech Corp.
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Attention: Chief Executive Officer
Telephone: (▇▇▇) ▇▇▇-▇▇▇▇
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
26
with a copy to:
MC Law Group
▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇ ▇. ▇▇▇▇▇, Esq.
Telephone: (▇▇▇) ▇▇▇-▇▇▇▇
Fax: (▇▇▇) ▇▇▇-▇▇▇▇
If to the Purchaser, to the address set forth on the
signature pages hereto.
9.5 EXPENSES. The parties hereto shall pay their own costs and
expenses in connection herewith, except that the Company shall pay or reimburse
the Purchaser, at or before the Closing, the flat sum of $15,000 for its legal
and due diligence expenses incurred in connection with the transactions
contemplated by this Agreement. The Company shall pay all fees and expenses of
any placement agents in connection with the transactions contemplated by this
Agreement pursuant to a separate agreement between such parties.
9.6 AMENDMENTS AND WAIVERS. Any term of this Agreement may be
amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or
prospectively), only with the written consent of the Company and the Purchaser;
provided, however, that any such amendment or waiver effected in accordance with
this paragraph shall be binding upon each holder of any Securities purchased
under this Agreement at the time outstanding, each future holder of all such
securities, and the Company.
9.7 SEVERABILITY. If one or more provisions of this Agreement
are held to be unenforceable under applicable law, such provision shall be
excluded from this Agreement and the balance of this Agreement shall be
interpreted as if such provision were so excluded and shall be enforceable in
accordance with its terms.
9.8 ENTIRE AGREEMENT. This Agreement, including the Exhibits
and Schedules hereto, the other Transaction Documents and other documents
contemplated hereby and thereby constitute the entire agreement among the
parties hereof with respect to the subject matter hereof and thereof and
supersede all prior agreements and understandings, both oral and written,
between the parties with respect to the subject matter hereof and thereof.
27
9.9 SURVIVAL. All representations, warranties, covenants and
agreements contained in this Agreement shall be deemed to be representations,
warranties, covenants and agreements as of the date hereof, except as expressly
provided to be made or deemed made as of another date. The representations and
warranties shall survive the execution and delivery of, and the Closing under,
this Agreement.
9.10 FURTHER ASSURANCES. The parties shall execute and deliver
all such further instruments and documents and take all such other actions as
may reasonably be required to carry out the transactions contemplated hereby and
to evidence the fulfillment of the agreements herein contained.
9.11 APPLICABLE LAW. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of Nevada without regard to
principles of conflicts of laws.
9.12 REMEDIES.
(a) The Purchaser shall be entitled to specific performance of
the Company's obligations under the Transaction Documents.
(b) The Company on the one hand and the Purchaser on the other
shall indemnify the other and hold it harmless from any loss, cost, expense or
fees (including reasonable attorneys' fees and expenses) arising out of any
breach of any of its representations, warranties, covenants or agreements in any
of the Transaction Documents, or arising out of the enforcement of this Section
9.12.
9.13 JURISDICTION. The parties hereby agree that all actions
or proceedings arising directly or indirectly from or in connection with this
Agreement shall be litigated only in the United States District Court for the
Northern District of Texas located in Dallas County, Dallas, Texas. The parties
consent and submit to the jurisdiction and venue of the foregoing courts and
consent that any process or notice of motion or other application to said court
or a judge thereof may be served inside or outside the State of Texas or the
Northern District of Texas (but with respect to any party hereto, such consent
shall not be deemed a general consent to jurisdiction and service for any third
parties) by registered mail, return receipt requested, directed to the party
being served at its address provided in or pursuant to this Agreement (and
service so made shall be deemed complete three (3) days after the same has been
posted as aforesaid) or by personal service or in such other manner as may be
permissible under the rules of said court. The Company hereby waives any right
to a jury trial in connection with any litigation pursuant to this Agreement.
[Signature Pages Follow]
28
IN WITNESS WHEREOF, the parties have executed this Agreement
as of the date first above written.
THE COMPANY:
BIOGENTECH CORP.
By: /s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
---------------------------------
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: CEO and President
29
THE PURCHASER:
GRYPHON MASTER FUND, L.P.
By: Gryphon Partners, L.P.,
its General Partner
By: Gryphon Management Partners, L.P.,
its General Partner
By: Gryphon Advisors, LLC,
its General Partner
By:/s/ ▇▇▇▇▇▇ ▇. Garden
------------------------------------
▇▇▇▇▇▇ ▇. Garden, Authorized Agent
Purchase Price: $1,000,000
Number of Warrant Shares: 104,167
Initial Conversion Price of Shares: $2.40
Initial Exercise Price of Warrant: $2.90
Address for Notices:
Gryphon Master Fund, L.P.
▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇ ▇. ▇▇▇▇▇▇▇
Telephone: (▇▇▇) ▇▇▇-▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
E-mail: ▇▇▇▇▇@▇▇▇▇▇▇▇▇▇.▇▇▇
with copies to:
▇▇▇▇▇▇ ▇. Garden, P.C.
▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇. Garden, Esq.
Telephone: (▇▇▇) ▇▇▇-▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
30
